Advertisement

Pfizer, analyst reports indicate first approval of new type of cancer drug could come early

The Associated Press
January 8, 2015 at 8:40PM

TRENTON, N.J. — The first in a new class of cancer medicines, Pfizer's Ibrance, appears poised for approval to treat advanced breast cancer within a few months and could quickly become a blockbuster, some analysts believe.

Pfizer shares rose 74 cents, or 2.3 percent, to $32.59 Thursday following analysts' forecasts that the U.S. Food and Drug Administration could approve Ibrance before its April 13 target decision date.

Their reports came just after the New York-based drugmaker said the FDA informed Pfizer it wouldn't convene a panel of outside experts to review testing data on the drug, known chemically as palbociclib. Such advisory panel meetings are often held, in addition to the review by FDA staff members, particularly when a drug is the first in a new class or there are concerns over effectiveness or side effects.

In recent years, the FDA has rejected many experimental drugs initially, requiring additional data and even new rounds of patient testing. But the FDA gave Ibrance priority review, part of its strategy to get potential breakthroughs to patients faster.

Pfizer also said it is already discussing with FDA staff the wording of the detailed package insert for the drug, another sign approval is likely soon. That would give Pfizer more of a head start on rivals in earlier stages of testing their own experimental drugs in the class, called CDK4/6 inhibitors.

Those drugs are believed to block enzymes, called CDK4 and 6, that help cancer cells divide uncontrollably.

Pfizer is seeking approval to market Ibrance for patients with advanced breast cancer whose growth is fueled by the hormone estrogen but not the growth factor HER2 — the majority of postmenopausal women with breast cancer. If approved, Ibrance would be given with an older cancer drug, letrozole, which reduces estrogen production. The two drugs would work synergistically.

Credit Suisse analyst Vamil Divan wrote to investors that he's "somewhat surprised" the FDA won't have an advisory committee meeting because the agency's decision would be based on a relatively small amount of data, a mid-stage Pfizer study called PALOMA 1.

Advertisement
Advertisement

It included 165 women who received Ibrance either alone or with letrozole. Among those receiving Ibrance, their cancer did not worsen for 20.2 months on average, twice as long as for women only receiving letrozole.

"We have consistently believed this is a product that the FDA sees value in and is committed to getting to the market as quickly as possible," Divan wrote.

He's forecasting Ibrance sales of about $420 million this year, $1 billion next year and $2 billion in 2017. Jeffries LLC analyst Jeffrey Holford forecasts sales of $5 billion by 2020. He wrote Thursday that he's very confident Ibrance will win approval on the first try, which would boost Pfizer stock about 5 percent.

Pfizer currently is running multiple, much larger studies of Ibrance among other women with breast cancer and, along with partners, is testing it against other cancer types, including head and neck, lung and prostate cancer and melanoma.

Meanwhile, Novartis AG and Eli Lilly and Co. are developing their own CDK4/6 inhibitors but are earlier in the testing process.

about the writer

about the writer

LINDA A. JOHNSON

More from Minnesota Star Tribune

See More
In this photo taken Monday, March 6, 2017, in San Francisco, released confidential files by The University of California of a sexual misconduct case, like this one against UC Santa Cruz Latin Studies professor Hector Perla is shown. Perla was accused of raping a student during a wine-tasting outing in June 2015. Some of the files are so heavily redacted that on many pages no words are visible. Perla is one of 113 UC employees found to have violated the system's sexual misconduct policies in rece

We respect the desire of some tipsters to remain anonymous, and have put in place ways to contact reporters and editors to ensure the communication will be private and secure.

card image
Advertisement
Advertisement

To leave a comment, .

Advertisement